L’Oréal has agreed to increase its shareholding in dermatology company Galderma to 20%, strengthening its foothold in medical aesthetics. The transaction will grant L’Oréal a board seat. Analysts estimate the deal exceeds 1.5 billion euros ($1.6 billion) based on Galderma’s valuation. Galderma, known for Restylane fillers and Dysport neurotoxin, reported over 4.5 billion euros ($4.9 billion) in revenue in 2024, with its aesthetics segment contributing over 60%. The investment underscores L’Oréal’s strategy to expand beyond consumer beauty into high-growth professional skin health.